المؤلفون: Italiano, Antoine, Cassier, Philippe A., Lin, Chia-Chi, Alanko, Tuomo, Peltola, Katriina J., Gazzah, Anas, Shiah, Her-Shyong, Calvo, Emiliano, Cervantes, Andrés, Roda, Desamparados, Tosi, Diego, Gao, Bo, Millward, Michael, Warburton, Lydia, Tanner, Minna, Englert, Stefan, Lambert, Stacie, Parikh, Apurvasena, Afar, Daniel E., Vosganian, Gregory, Moreno, Victor

المساهمون: HUS Comprehensive Cancer Center, Department of Oncology

مصطلحات موضوعية: Budigalimab, Head and neck squamous cell cancer, Non-small cell lung cancer, PD-1 inhibitor, 3122 Cancers

وصف الملف: application/pdf

العلاقة: AbbVie and the authors thank the patients who participated in this clinical trial, the study coordinators, and support staff. We would like to acknowledge James P. Sheridan (Drug Metabolism Pharmacokinetics & Bioanalysis Department, AbbVie) for performing the preclinical and clinical pharmacokinetic studies, and Fiona Harding (Oncology Discovery, AbbVie) for creating, selecting, and validating the ABBV-181 antibody and filing the in vitro/in vivo IND supporting reports, including summaries of the preclinical activity of ABBV-181. Biomarker sample testing was performed by Covance, Princeton, NJ (flow cytometry), Mosaic Laboratories, Lake Forest, CA (immunohistochemistry), and Myriad RBM, Austin, TX (cytokine testing). This study was funded by AbbVie Inc., North Chicago, IL, USA. Medical writing support was provided by Joanne Franklin, PhD, CMPP, Aptitude Health, The Hague, the Netherlands, funded by AbbVie. AbbVie and the authors thank the patients who participated in this clinical trial, the study coordinators, and support staff. We would like to acknowledge James P. Sheridan (Drug Metabolism Pharmacokinetics & Bioanalysis Department, AbbVie) for performing the preclinical and clinical pharmacokinetic studies, and Fiona Harding (Oncology Discovery, AbbVie) for creating, selecting, and validating the ABBV-181 antibody and filing the in vitro/in vivo IND supporting reports, including summaries of the preclinical activity of ABBV-181. Biomarker sample testing was performed by Covance, Princeton, NJ (flow cytometry), Mosaic Laboratories, Lake Forest, CA (immunohistochemistry), and Myriad RBM, Austin, TX (cytokine testing). This study was funded by AbbVie Inc., North Chicago, IL, USA. Medical writing support was provided by Joanne Franklin, PhD, CMPP, Aptitude Health, The Hague, the Netherlands, funded by AbbVie. Antoine Italiano: Consulting/advisory role: Roche, Daiichi Sankyo, Immune Design, Epizyme, Bayer, Lilly; honoraria: Bayer, Daiichi Sankyo, Lilly, Epizyme, Novartis, Roche; research funding: Roche, Bayer, AstraZeneca/MedImmune, PharmaMar, MSD Oncology, Merck Serono. Philippe A. Cassier: Honoraria: Novartis, Roche/Genentech, Blueprint Medicines, Amgen; research funding: Novartis, Roche/Genentech, Lilly, Blueprint Medicines, Bayer, AstraZeneca, Celgene, Plexxikon, AbbVie, Bristol-Myers Squibb, Merck Serono, Merck Sharp & Dohme; Consultancy/advisory role: Merck Serono, Roche/Genentech. Chia-Chi Lin: Consulting/advisory role: Novartis, Boehringer Ingelheim, Blueprint Medicines; travel/accommodations/expenses: Lilly, Daiichi Sankyo, BeiGene, Novartis; honoraria: Novartis, Roche, Daiichi Sankyo. Tuomo Alanko: Consulting/advisory role: Bayer, Baxalta/Shire, BMS, Celgene, Eli Lilly, MSD, Nordic Drugs, Roche, Kaiku Health; research funding: AbbVie, Bayer, Boehringer Ingelheim, BMS, Debiopharm, Eli Lilly, Incyte, MSD, Pfizer, Roche; travel/accommodations/expenses: Baxalta/Shire, BMS, MSD, Pfizer, Roche. Katriina J. Peltola: Consulting/advisory role: Orion Pharma, BMS, MSD, Novartis, Pfizer, Ipsen, Roche, Varian; stockholder: Faron Pharmaceuticals; speakers’ bureau: BMS, Pfizer, MSD; expert testimony: Ipsen; travel/accommodations/expenses: Roche, BMS; research funding: AbbVie, Bayer, BMS, MSD, Roche, Exelixis, Orion Pharma, Eisai, Novartis. Anas Gazzah: Travel, accommodations, congress registration expenses: Boehringer Ingelheim, Novartis, Pfizer, Roche; consultant/expert role: Novartis; principal/sub-investigator of clinical trials: Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X BVBA, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Aveo, Bayer HealthCare Ag, BBB Technologies BV, BeiGene, BioAlliance Pharma, BioNTech AG, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co., Clovis Oncology, Daiichi Sankyo, Debiopharm SA, Eisai, Exelixis, Forma, GamaMabs, Genentech, Inc., Gilead Sciences, Inc, GlaxoSmithKline, Glenmark Pharmaceuticals, H3 Biomedicine, Inc, F. Hoffmann-La Roche AG, Incyte Corporation, Innate Pharma, Servier IRIS, Janssen, Kura Oncology, Kyowa Kirin Pharmaceutical Development, Lilly, Loxo Oncology, Lytix Biopharma AS, MedImmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology NV, OncoEthix, OncoMed, Oncopeptides, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Pfizer, PharmaMar, Pierre Fabre, Rigontec GmbH, Roche, Sanofi Aventis, Sierra Oncology, Taiho Pharma, Tesaro, Inc, Tioma Therapeutics, Inc., Xencor; research grants: AstraZeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi; nonfinancial support (drug supplied): AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Johnson & Johnson, Lilly, MedImmune, Merck, NH TherAGuix, Pfizer, Roche. Her-Shyong Shiah: The author declares no potential conflicts of interest. Emiliano Calvo: Consulting/advisory role: Novartis, Nanobiotix, Janssen-Cilag, PsiOxus, Seattle Genetics, EUSA Pharma, AbbVie, Celgene, AstraZeneca, Guidepoint Global, Roche/Genentech, GLG, Pfizer, Servier, amcure; speakers’ bureau: Novartis; research funding: AstraZeneca, BeiGene, Novartis, START; travel/accommodations/expenses reimbursement: Roche/Genentech; honoraria: HM Hospitales Group; stock/ownership interests: START, Oncoart Associated, International Cancer Consultants; president and founder of Foundation INTHEOS . Andrés Cervantes: Institutional research funding: AbbVie, Genentech, Merck Serono, BMS, MSD, Roche, BeiGene, Bayer, Servier, Lilly, Novartis, Takeda, Astellas, FibroGen; advisory board or speaker fees: Merck Serono, Roche, Bayer, Servier, Pierre Fabre. Desamparados Roda: The author declares no potential conflicts of interest. Diego Tosi: Consulting/advisory role: BioMarin (immediate family member); research funding: Novartis, Astellas, Janssen; patent pending on a new drug combination for prostate cancer treatment; travel/accommodations/expenses: Janssen, Pfizer, Astellas Pharma; immediate family member had travel/accommodations/expenses from Nutricia and Amicus. Bo Gao: Consulting/advisory role: MSD. Michael Millward: Consulting/advisory role: Merck Sharp & Dohme, Bristol-Myers Squibb, AstraZeneca, Roche, Pfizer, Takeda, Novartis; conference travel/support: Merck Sharp & Dohme, Bristol-Myers Squibb, AstraZeneca, Roche. Lydia Warburton: Travel/accommodations/expenses: MSD, Merck. Minna Tanner: Consulting/advisory role: Roche, Novartis, Pfizer; speakers’ bureau: Roche, Novartis, Pfizer, Amgen. Gregory Vosganian: Former employee of AbbVie and may own stock. Stefan Englert, Stacie Lambert, Apurvasena Parikh, Daniel E. Afar: AbbVie employees and may own stock. Victor Moreno: Consulting fees: Merck, BMS, Janssen, Pieris; travel/accommodations: Regeneron/Sanofi; presentations: Nanobiotix; educational grant: Medscape/Bayer.; Italiano , A , Cassier , P A , Lin , C-C , Alanko , T , Peltola , K J , Gazzah , A , Shiah , H-S , Calvo , E , Cervantes , A , Roda , D , Tosi , D , Gao , B , Millward , M , Warburton , L , Tanner , M , Englert , S , Lambert , S , Parikh , A , Afar , D E , Vosganian , G & Moreno , V 2022 , ' First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma ' , Cancer Immunology, Immunotherapy , vol. 71 , no. 2 , pp. 417-431 . https://doi.org/10.1007/s00262-021-02973-wTest; 85109344549; 82232dae-2a73-44eb-98d3-0e87d81835e0; http://hdl.handle.net/10138/354706Test

الإتاحة: http://hdl.handle.net/10138/354706Test

المؤلفون: Yang, James Chih-Hsin, Su, Wu-Chou, Chiu, Chao-Hua, Shiah, Her-Shyong, Lee, Kang-Yun, Hsia, Te-Chun, Uno, Makiko, Crawford, Nigel, Terakawa, Hiroshi, Chen, Wen-Chi, Takayama, Gensuke, Hsu, Ching, Hong, Ying, Saintilien, Carline, McGill, Joseph, Chang, Gee-Chen

المصدر: Investigational New Drugs ; volume 41, issue 2, page 306-316 ; ISSN 0167-6997 1573-0646

مصطلحات موضوعية: Pharmacology (medical), Pharmacology, Oncology

الإتاحة: https://doi.org/10.1007/s10637-023-01341-yTest

المؤلفون: Dai, Ming-Shen, Chao, Ta-Chung, Chiu, Chang-Fang, Lu, Yen-Shen, Shiah, Her-Shyong, Jackson, Christopher G. C. A., Hung, Noelyn, Zhi, Jianguo, Cutler, David L., Kwan, Rudolf, Kramer, Douglas, Chan, Wing-Kai, Qin, Albert, Tseng, Kuan-Chiao, Hung, Cheung Tak, Chao, Tsu-Yi

المساهمون: PharmaEssentia Corporation, Athenex

المصدر: Therapeutic Advances in Medical Oncology ; volume 15 ; ISSN 1758-8359 1758-8359

مصطلحات موضوعية: Oncology

الإتاحة: https://doi.org/10.1177/17588359231183680Test

المؤلفون: Shiah, Her-Shyong, Lee, Chia-Jung, Lee, Fang-Yu, Tseng, Sung-Hui, Chen, Shih-Han, Wang, Ching-Chiung

المصدر: Frontiers in Pharmacology ; volume 14 ; ISSN 1663-9812

مصطلحات موضوعية: Pharmacology (medical), Pharmacology

الإتاحة: https://doi.org/10.3389/fphar.2023.1106030Test

المؤلفون: Chiang, Cho‐Han, Chiang, Cho‐Hung, Hsia, Yuan Ping, Jaroenlapnopparat, Aunchalee, Horng, Chuan‐Sheng, Wong, Kit Yee, Wang, Shih‐Syuan, Chang, Yu‐Cheng, Chen, Brian Shiian, Luan, Yu‐Ze, Wang, Chun‐Hao, Neilan, Tomas G., Chiang, Cho‐Hsien, Peng, Cheng‐Ming, Shiah, Her‐Shyong

المصدر: Journal of Gastroenterology & Hepatology; May2024, Vol. 39 Issue 5, p902-907, 6p

مصطلحات موضوعية: COLORECTAL cancer, SODIUM-glucose cotransporters, SODIUM-glucose cotransporter 2 inhibitors, DIABETES, PEOPLE with diabetes, TYPE 2 diabetes

المؤلفون: Lu, Shun, Wang, Qiming, Zhang, Guojun, Dong, Xiaorong, Yang, Cheng-Ta, Song, Yong, Chang, Gee-Chen, Lu, You, Pan, Hongming, Chiu, Chao-Hua, Wang, Zhehai, Feng, Jifeng, Zhou, Jianying, Xu, Xingxiang, Guo, Renhua, Chen, Jianhua, Yang, Haihua, Chen, Yuan, Yu, Zhuang, Shiah, Her-Shyong, Wang, Chin-Chou, Yang, Nong, Fang, Jian, Wang, Ping, Wang, Kai, Hu, Yanping, He, Jianxing, Wang, Ziping, Shi, Jianhua, Chen, Shaoshui, Wu, Qiong, Sun, Changan, Li, Chuan, Wei, Hongying, Cheng, Ying, Su, Wu-Chou, Hsia, Te-Chun, Cui, Jiuwei, Sun, Yuping, Ou, Sai-Hong Ignatius, Zhu, Viola W., Chih-Hsin Yang, James

المصدر: Journal of Thoracic Oncology ; volume 17, issue 3, page 411-422 ; ISSN 1556-0864

الإتاحة: https://doi.org/10.1016/j.jtho.2021.10.024Test
https://api.elsevier.com/content/article/PII:S1556086421033232?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1556086421033232?httpAccept=text/plainTest

المؤلفون: Italiano, Antoine, Cassier, Philippe A., Lin, Chia Chi, Alanko, Tuomo, Peltola, Katriina J., Gazzah, Anas, Shiah, Her Shyong, Calvo, Emiliano, Cervantes, Andrés, Roda, Desamparados, Tosi, Diego, Gao, Bo, Millward, Michael, Warburton, Lydia, Tanner, Minna, Englert, Stefan, Lambert, Stacie, Parikh, Apurvasena, Afar, Daniel E., Vosganian, Gregory, Moreno, Victor

المساهمون: Tampere University, Department of Oncology

مصطلحات موضوعية: 3122 Cancers

وصف الملف: fulltext

العلاقة: Cancer Immunology, Immunotherapy; https://trepo.tuni.fi/handle/10024/133491Test; URN:NBN:fi:tuni-202107296405

الإتاحة: https://doi.org/10.1007/s00262-021-02973-wTest
https://trepo.tuni.fi/handle/10024/133491Test

المؤلفون: Tsai, Hui-Jen, Shiah, Her-Shyong, Chang, Jang-Yang, Su, Wu-Chou, Chiang, Nai-Jung, Chen, Li-Tzong

المصدر: Scientific Reports ; volume 11, issue 1 ; ISSN 2045-2322

مصطلحات موضوعية: Multidisciplinary

الإتاحة: https://doi.org/10.1038/s41598-021-84279-6Test
https://www.nature.com/articles/s41598-021-84279-6.pdfTest
https://www.nature.com/articles/s41598-021-84279-6Test

المؤلفون: Lee, Hsin-Lun, Chiou, Jeng-Fong, Wang, Peng-Yuan, Lu, Long-Sheng, Shen, Chia-Ning, Hsu, Han-Lin, Burnouf, Thierry, Ting, Lai-Lei, Chou, Pai-Chien, Chung, Chi-Li, Lee, Kai-Ling, Shiah, Her-Shyong, Liu, Yen-Lin, Chen, Yin-Ju

المساهمون: Swinburne University of Technology

المصدر: Cancers, Vol. 12, no. 11 (Nov 2020), 3394

العلاقة: http://hdl.handle.net/1959.3/458972Test; https://doi.org/10.3390/cancers12113394Test

الإتاحة: https://doi.org/10.3390/cancers12113394Test
http://hdl.handle.net/1959.3/458972Test

المؤلفون: de Bono, Johann, Lin, Chia-Chi, Chen, Li-Tzong, Corral, Jesus, Michalarea, Vasiliki, Rihawi, Karim, Ong, Michael, Lee, Jih-Hsiang, Hsu, Chih-Hung, Yang, James Chih-Hsin, Shiah, Her-Shyong, Yen, Chia-Jui, Anthoney, Alan, Jove, Maria, Buschke, Susanne, Fuertig, René, Schmid, Ulrike, Goeldner, Rainer-Georg, Strelkowa, Natalja, Huang, Dennis Chin-Lun, Bogenrieder, Thomas, Twelves, Chris, Cheng, Ann-Lii

المساهمون: Boehringer Ingelheim

المصدر: British Journal of Cancer ; volume 122, issue 9, page 1324-1332 ; ISSN 0007-0920 1532-1827

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1038/s41416-020-0774-1Test
http://www.nature.com/articles/s41416-020-0774-1.pdfTest
http://www.nature.com/articles/s41416-020-0774-1Test